Kala Pharmaceuticals Announces Preferred Position for EYSUVIS(TM) on Cigna
-- Commercial formulary coverage effective May 15, 2021 --
WATERTOWN, Mass.--(BUSINESS WIRE)--March 16, 2021--
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Cigna has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021.
"We are pleased to announce the addition of EYSUVIS to Cigna's preferred formulary, reflecting a significant expansion of our commercial coverage and important progress toward our goal of securing broad patient access, " said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals. "We look forward to continuing to engage with other commercial and Medicare Part D health plans as we execute on our strategy to optimize coverage, with the goal of delivering EYSUVIS as the preferred prescription therapy for the millions of people in the United States who suffer from dry eye disease flares."
EYSUVIS was approved in October 2020 as the first and only prescription therapy indicated specifically for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS became commercially available in the United States in January 2021 and is available through both national and regional U.S. pharmaceutical distribution centers, as well as local retail pharmacies or home delivery.
